Cannabinoids and Cancer

Dear Colleagues, 

The endocannabinoid system (ECS) is a complex array of endogenous cannabinoid ligands, cannabinoid receptors (CBR), metabolic enzymes and transporters that are responsible for the biosynthesis and degradation of endocannabinoids. ECS regulates homeostasis within the organism and controls housekeeping processes, such as regulation of appetite, energy metabolism and immune functions. There are three main categories of cannabinoids: endogenous cannabinoids, synthetic cannabinoids and phytocannabinoids. Endogenous cannabinoids are those produced in the human body or in animals and include anandamide or arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG). Phytocannabinoids are cannabinoids derived from extracts of the plant Cannabis sativa or indica L. There are more than 100 different phytocannabinoids, of which the most common and bioactive are THC (Δ⁹-tetrahydrocannabinol), CBD (cannabidiol), and CBN (cannabinol). Many studies have reported that the ECS could be a new interesting target for the treatment of many cancer types. The potential of modulating the ECS has attracted interest in cancer research and has been extensively studied, particularly for its anticancer, anti-proliferative, anti-angiogenic, proapoptotic, and anti-metastatic activity. Several types of cancer have been shown to be suppressed by cannabinoids such as breast, glioblastoma, pancreatic, and prostate cancer. In addition, emerging evidence suggests that cannabinoids may improve the efficacy of available therapeutic options for cancer treatments such as chemotherapy, immunotherapy, radiation, surgery, and the use of targeted therapy. This Special Issue intends to publish original research, expert opinions, and reviews to add to the growing knowledge on cannabinoids and cancer. Short reports and methodological papers will also be considered.

Prof. Dr. Marco Falasca
Prof. Dr. Mauro Maccarrone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.